医学
咽炎
重症监护医学
临床试验
临床终点
公共卫生
疾病
流行病学
化脓性链球菌
脓疱病
儿科
免疫学
急性风湿热
传输(电信)
风湿热
梅德林
疫苗效力
家庭医学
心脏病
临床微生物学
传染病(医学专业)
不利影响
替代医学
临床研究
协商一致会议
作者
Kimberly Davis,Kirsty Le Doaré,Johan Vekemans,Pierre Gsell,Wilder-Smith Annelies,Annette Kraus,Somyoung Cho,Liesl Zühlke,Scott H. Wirth,Joselyn Rwebembera,James Marangou,Marco Cavaleri,Yasir Bin Nisar,Christopher J. Gregory,Chris Van Beneden,Shiranee Sriskandan,Edwin Asturias,Alma Fulurija,Jim Ackland,Andrea Z. Beaton
出处
期刊:Vaccine
[Elsevier BV]
日期:2026-11-03
卷期号:96: 129262-129262
标识
DOI:10.1016/j.vaccine.2026.129262
摘要
Streptococcus pyogenes (group A Streptococcus; Strep A) causes a broad spectrum of diseases ranging from pharyngitis and skin infections to invasive disease and immune-mediated complications including acute rheumatic fever (ARF) and rheumatic heart disease (RHD). RHD remains one of the most important causes of cardiovascular mortality in young people globally, affecting more than 55 million individuals and causing over 370,000 deaths annually, predominantly in low- and middle-income countries. Despite this substantial burden, no licensed Strep A vaccine exists. A critical barrier to vaccine development is that there are many potential clinical trial endpoints capable of supporting regulatory approval while demonstrating meaningful public health impact. However, research gaps remain before these can be fully realised. To address this challenge, the World Health Organization (WHO) and the Strep A Vaccine Global Consortium (SAVAC) convened two international expert consultations in London (September 2024) and Geneva (October 2025). Participants reviewed emerging scientific evidence, epidemiology, and regulatory considerations to define potential clinical development pathways and priority endpoints for Strep A vaccines. Consensus emerged that prevention of Strep A pharyngitis in children represents a feasible primary endpoint for initial proof-of-efficacy trials and potential licensure. Impetigo in children was recognized as an important endpoint, particularly in high-burden settings or where it contributes substantially to transmission and severe invasive infections or progression to RHD. Although prevention of RHD and invasive disease is the ultimate public health objective, advanced RHD was considered infeasible as a pre-licensure endpoint. Early RHD detected by echocardiography was identified as a promising intermediate outcome, but further epidemiological and validation studies could increase confidence in its use in pivotal trials. A clinical development pathway is proposed in which initial licensure is supported by efficacy against pharyngitis and possibly impetigo or early RHD with further evaluation of other severe outcomes such as invasive infections through large-scale trials and post-licensure studies. This pathway informs updates to the WHO Preferred Product Characteristics and Research and Development Roadmap and provides a coordinated strategy to accelerate the development and equitable global introduction of Strep A vaccines.
科研通智能强力驱动
Strongly Powered by AbleSci AI